Rivastigmine
23 NDCs across 7 manufacturers|17 Generic,6 Brand
Rivastigmine is used to treat alzheimer disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Jul 6, 2007, and the first generic was approved Aug 31, 2015. FDA's Orange Book lists 18 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $79 million on Rivastigmine across 398,000 claims for 82,000 beneficiaries.
Rivastigmine is available as 23 NDCs from 7 manufacturers (17 generic, 6 brand), with NADAC prices from $1.75 to $22.01 per EA — the most expensive product costs about 13× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
23
17G / 6B
Manufacturers
7
competing in market
Price Spread
$1.75 – $22.01
per EA
7d Activity
avg -1.9% WoW · of 23 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Sandoz Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Cholinesterase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
7 manufacturers producing RIVASTIGMINE
Frequently Asked Questions
What is Rivastigmine used to treat?
Rivastigmine is used to treat alzheimer disease, per the National Library of Medicine's MED-RT classification.
When did Rivastigmine become available as a generic?
FDA approved the first generic Rivastigmine (ANDA) on Aug 31, 2015. The Orange Book currently lists 18 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Rivastigmine?
In 2024, Medicare Part D spent $79 million on Rivastigmine across 398,000 claims for 82,000 beneficiaries.
How many Rivastigmine products are on the market?
The Rivastigmine drug market contains 23 NDCs from 7 manufacturers — 17 generic and 6 brand products.
What is the price range for Rivastigmine?
NADAC reference prices for Rivastigmine range from $1.7517 to $22.0078 per EA — the most expensive product costs about 13× the cheapest.
Is generic Rivastigmine cheaper than brand?
The average generic NADAC for Rivastigmine is $1.7781 per EA, versus $21.8961 for brand-labeled products — brand versions average about 12× the generic price.
Which manufacturers make Rivastigmine?
7 manufacturers list Rivastigmine in NADAC. Ranked by number of NDCs, the largest are Sandoz Inc. (6), Novartis Pharmaceuticals Corporation (3), Amneal Pharmaceuticals LLC (3), Mylan Pharmaceuticals Inc. (3), Zydus Pharmaceuticals (USA) Inc. (3).
How has the price of Rivastigmine changed recently?
Over the past 7 days, 0 Rivastigmine NDCs rose and 19 fell, with a market-wide average change of -1.9%.